发明授权
- 专利标题： Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
-
申请号： US17522284申请日： 2021-11-09
-
公开(公告)号： US12098199B2公开(公告)日： 2024-09-24
- 发明人: Huamao Wang , Bo Song , Xiumei Cai
- 申请人： CRAGE medical Co., Limited
- 申请人地址： CN Hong Kong
- 专利权人： CRAGE MEDICAL CO., LIMITED
- 当前专利权人： CRAGE MEDICAL CO., LIMITED
- 当前专利权人地址： CN Hong Kong
- 代理机构： Wilson Sonsini Goodrich & Rosati
- 优先权： CN 1410341504.X 2014.07.17
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; A61K35/17 ; A61K48/00 ; C07K14/705 ; C07K14/725 ; C07K19/00 ; C12N5/10 ; C12N15/62 ; C12N15/867 ; A61K35/12
摘要：
Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.
公开/授权文献
信息查询
